转移性去势抵抗性前列腺癌患者中[177Lu]Lu-PSMA-I&T的真实世界临床经验:超越VISION和TheraP标准
单中心回顾性研究纳入50例转移性去势抵抗性前列腺癌患者,2022年2月至2023年8月接受[177Lu]Lu-PSMA-I&T靶向放射性核素治疗,每周期固定7.4 GBq/100µg、最多6周期。PSA下降≥50%和≥70%分别为16%和10%,放射学缓解11%;中位无进展生存7.7个月(95%CI 4.0-11.3),中位总生存8.1个月(95%CI 5.0-11.3)。作者结论为耐受性和安全性良好,但真实世界疗效似乎低于使用不同放射性配体[177Lu]Lu-PSMA-617的近期3期临床试验数据。
要点
- 50例经重度治疗mCRPC患者接受[177Lu]Lu-PSMA-I&T,每周期固定7.4 GBq/100µg、最多6周期。
- PSA下降≥50%为16%、≥70%为10%,放射学缓解11%,中位PFS 7.7个月、中位OS 8.1个月。
- 治疗相关不良事件以1-2级为主(88%),3/4级占12%,无3级及以上口干症。
核心结论
- 在经重度治疗的mCRPC患者中,[177Lu]Lu-PSMA-I&T靶向放射性核素治疗耐受性良好且安全,但真实世界疗效似乎低于使用不同放射性配体[177Lu]Lu-PSMA-617的近期3期临床试验数据。
- 作者认为,进一步研究可能显示mCRPC患者在更早治疗阶段启动[177Lu]Lu-PSMA是否能更多获益。
研究设计与样本
- 单中心三级转诊大学医院的回顾性研究。
- 纳入2022年2月至2023年8月期间作为标准治疗接受[177Lu]Lu-PSMA-I&T靶向放射性核素治疗的mCRPC患者。
- 治疗方案为每周期固定活度7.4 GBq/100µg [177Lu]Lu-PSMA-I&T,最多6个周期。
- 共纳入50例mCRPC患者。
主要发现
- 50例患者中84%既往接受过两线紫杉烷类化疗和至少一线雄激素受体信号抑制剂治疗。
- 每例患者中位接受2个周期(IQR 1-6)[177Lu]Lu-PSMA-I&T,共126个周期。
- PSA下降≥50%和≥70%的患者分别占16%和10%,放射学缓解占11%。
- 共观察到68例治疗相关不良事件,其中88%主要为1-2级;3/4级治疗相关不良事件占12%;未报告3级或以上口干症。
- 中位无进展生存期为7.7个月(95%CI 4.0-11.3),中位总生存期为8.1个月(95%CI 5.0-11.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report real-world clinical experience with [177Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital. METHODS: Patients with mCRPC who were treated with [177Lu]Lu-PSMA-I&T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.4 GBq/100µg [177Lu]Lu-PSMA-I&T per cycle. RESULTS: 50 patients with mCRPC were included, of them 84% had prior therapy with two lines of taxane-based chemotherapy treated and at least one line of androgen receptor signaling inhibitor. A total of 126 cycles with a median of 2 cycles (IQR 1-6) [ 177Lu]Lu-PSMA-I&T were administered per patient. PSA declines of ≥ 50% and ≥ 70% were achieved in 16% and 10% of the patients, respectively. Radiological response was achieved in 11% of the patients. In total, 68 treatment-related Adverse Events (TRAEs) were observed, mainly grade 1-2 in 88% of cases. Grade 3/4 TRAEs were observed in 12% of cases. No grade 3 or higher xerostomia was reported. Median progression-free survival was 7.7 months (95% CI 4.0-11.3) and median overall survival was 8.1 months (95% CI 5.0-11.3). CONCLUSION: In heavily pretreated patients with mCRPC, treatment of [177Lu]Lu-PSMA-I&T TRT is well tolerated and safe, but real-world efficacy of [177Lu]Lu-PSMA appears lower compared to data from recent phase-3 clinical trials using a different radioligand [177Lu]Lu-PSMA-617. Further studies may show whether patients with mCRPC benefit more from [177Lu]Lu-PSMA when initiated at an earlier stage of treatment.
引用
- Ling SW, de Lussanet de la Sablonière Q, Ananta M, et al. First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria. Eur J Nucl Med Mol Imaging. 2025. PMID: 39825041. doi:10.1007/s00259-025-07082-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。